These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 549003)

  • 21. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
    Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
    Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)].
    Buge A; Poisson M; Masson S; Bleibel JM; Lafforgue B; Raymond P; Jaudon MC
    Nouv Presse Med; 1978 Jun; 7(23):2053-9. PubMed ID: 673773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic renal failure and magnesium metabolism.
    Lindeman RD
    Magnesium; 1986; 5(5-6):293-300. PubMed ID: 3807422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure.
    Fernández E; Amoedo ML; Montoliu J
    Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring.
    Fenwick S; Roberts EA; Mahesh BS; Roberts NB
    Ann Clin Biochem; 2005 Mar; 42(Pt 2):149-52. PubMed ID: 15829127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone histoquantitative findings and histochemical staining reactions for aluminium in chronic renal failure patients treated with haemodialysis fluids containing high and low concentrations of aluminium.
    McClure J; Fazzalari NL; Fassett RG; Pugsley DJ
    J Clin Pathol; 1983 Nov; 36(11):1281-7. PubMed ID: 6630577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of serum aluminium monitoring in dialysis patients: a multicentre study.
    D'Haese PC; Clement JP; Elseviers MM; Lamberts LV; Van de Vyver FL; Visser WJ; De Broe ME
    Nephrol Dial Transplant; 1990; 5(1):45-53. PubMed ID: 2109284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders.
    O'Brien AA; Moore DP; Keogh JA
    Ir J Med Sci; 1990 Mar; 159(3):74-6. PubMed ID: 2361823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in bone histoquantitative parameters and histochemical staining reactions for aluminium in a group of patients with chronic renal failure following a reduction in the aluminium concentration of the haemodialysis fluid.
    McClure J; Fazzalari NL; Fassett RG; Pugsley PG
    J Clin Pathol; 1984 Jul; 37(7):743-7. PubMed ID: 6747011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum aluminium in haemodialysis patients: relation to osteodystrophy, encephalopathy and aluminium hydroxide consumption.
    Heaf JG; Nielsen LP
    Miner Electrolyte Metab; 1984; 10(6):345-50. PubMed ID: 6503890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.
    Ellis HA; McCarthy JH; Herrington J
    J Clin Pathol; 1979 Aug; 32(8):832-44. PubMed ID: 389958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between hair, serum and bone aluminium in hemodialyzed patients.
    Chappuis P; de Vernejoul MC; Paolaggi F; Rousselet F
    Clin Chim Acta; 1989 Feb; 179(3):271-8. PubMed ID: 2714000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Histochemical localization of aluminum deposits in bones and their relation to the clinical and histomorphometric findings in patients with chronic renal failure].
    Stein G; Herzfeld T; Abendroth K; Günther K; Fünfstück F; Sperschneider H; Michael R
    Z Urol Nephrol; 1986 Oct; 79(10):577-86. PubMed ID: 3811646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Aluminium accumulation in patients with chronic renal failure (author's transl)].
    Tsukamoto Y; Marumo F; Iwanami S; Nango H; Higashishiba H; Nakazawa R
    Nihon Jinzo Gakkai Shi; 1980 Jun; 22(6):721-8. PubMed ID: 7206332
    [No Abstract]   [Full Text] [Related]  

  • 40. Aluminium intoxication in undialysed adults with chronic renal failure.
    Russo LS; Beale G; Sandroni S; Ballinger WE
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):697-700. PubMed ID: 1527541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.